Stonepine Capital Management LLC Takes $1.71 Million Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Stonepine Capital Management LLC bought a new position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 300,000 shares of the biotechnology company’s stock, valued at approximately $1,713,000. Aurinia Pharmaceuticals makes up 1.6% of Stonepine Capital Management LLC’s holdings, making the stock its 13th biggest holding. Stonepine Capital Management LLC owned 0.21% of Aurinia Pharmaceuticals at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. Eagle Asset Management Inc. bought a new position in Aurinia Pharmaceuticals in the fourth quarter worth $92,000. Armistice Capital LLC lifted its holdings in shares of Aurinia Pharmaceuticals by 57.7% during the 4th quarter. Armistice Capital LLC now owns 9,536,000 shares of the biotechnology company’s stock worth $85,729,000 after acquiring an additional 3,488,000 shares during the period. Privium Fund Management UK Ltd acquired a new stake in shares of Aurinia Pharmaceuticals during the 4th quarter valued at about $593,000. Vermillion & White Wealth Management Group LLC bought a new stake in Aurinia Pharmaceuticals in the fourth quarter valued at about $30,000. Finally, Cantor Fitzgerald L. P. raised its position in Aurinia Pharmaceuticals by 44.7% in the fourth quarter. Cantor Fitzgerald L. P. now owns 145,310 shares of the biotechnology company’s stock worth $1,306,000 after purchasing an additional 44,855 shares in the last quarter. Institutional investors and hedge funds own 36.83% of the company’s stock.

Insider Activity at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, insider Scott Michael Habig sold 18,249 shares of the company’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $5.31, for a total transaction of $96,902.19. Following the transaction, the insider now owns 456,338 shares of the company’s stock, valued at approximately $2,423,154.78. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 4.30% of the stock is currently owned by company insiders.

Aurinia Pharmaceuticals Trading Up 0.7 %

AUPH stock opened at $7.33 on Tuesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.33 and a quick ratio of 4.82. The stock has a market capitalization of $1.05 billion, a price-to-earnings ratio of -17.05 and a beta of 1.44. The business has a fifty day moving average price of $6.36 and a 200 day moving average price of $5.67. Aurinia Pharmaceuticals Inc. has a fifty-two week low of $4.71 and a fifty-two week high of $10.05.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings results on Thursday, August 1st. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.01. Aurinia Pharmaceuticals had a negative net margin of 24.31% and a negative return on equity of 11.84%. The business had revenue of $57.10 million for the quarter, compared to the consensus estimate of $54.25 million. During the same quarter in the prior year, the company earned ($0.08) EPS. The firm’s quarterly revenue was up 37.6% on a year-over-year basis. Analysts expect that Aurinia Pharmaceuticals Inc. will post 0.13 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on AUPH. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price objective on shares of Aurinia Pharmaceuticals in a report on Friday, September 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $10.00 price target on shares of Aurinia Pharmaceuticals in a research note on Monday, September 16th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.